Loading...
A Multidimensional Analytical Comparison of Remicade and the Biosimilar Remsima
Pisupati, Karthik Tian, Yuwei Okbazghi, Solomon Zeray Benet, Alexander Ackermann, Rose Ford, Michael Saveliev, Sergei Hosfield, Christopher M. Urh, Marjeta Carlson, Eric
Pisupati, Karthik
Tian, Yuwei
Okbazghi, Solomon Zeray
Benet, Alexander
Ackermann, Rose
Ford, Michael
Saveliev, Sergei
Hosfield, Christopher M.
Urh, Marjeta
Carlson, Eric
Citations
Altmetric:
Abstract
In April 2016, the Food and Drug Administration approved the first biosimilar monoclonal antibody (mAb) – Inflectra/Remsima (Celltrion) based off the original product Remicade (infliximab, Janssen). Biosimilars promise significant cost savings for patients, but the unavoidable differences between innovator and copycat biologics raise questions regarding product interchangeability. In this study, Remicade and Remsima were examined by native mass spectrometry, ion mobility and quantitative peptide mapping. The levels of oxidation, deamidation and mutation of individual amino acids were remarkably similar. We found different levels of C-terminal truncation, soluble protein aggregates and glycation that all likely have a limited clinical impact. Importantly, we identified over 25 glycoforms for each product and observed glycoform population differences, with afucosylated glycans accounting for 19.7% of Remicade and 13,2% of Remsima glycoforms, which translated into a 2-fold reduction in FcγRIIIa binding for Remsima. While this difference was acknowledged in Remsima regulatory filings, our glycoform analysis and receptor binding results appear to be somewhat different from the published values, likely due to methodological differences between laboratories and improved glycoform identification by our laboratory using a peptide map-based method. Our mass spectrometry based analysis provides rapid and robust analytical information vital for biosimilar development. We have demonstrated the utility of our multiple attribute monitoring workflow using the model mAbs Remicade and Remsima, and have provided a template for analysis of future mAb biosimilars.
Description
Date
2017-04
Journal Title
Journal ISSN
Volume Title
Publisher
American Chemical Society
Collections
Files
Research Projects
Organizational Units
Journal Issue
Keywords
Biosimilars, Monoclonal antibodies, Ion-mobility, Glycosylation, Mass spectrometry
Citation
Pisupati, K., Tian, Y., Okbazghi, S., Benet, A., Ackermann, R., Ford, M., … Schwendeman, A. (2017). A Multidimensional Analytical Comparison of Remicade and the Biosimilar Remsima. Analytical Chemistry, 89(9), 4838–4846. http://doi.org/10.1021/acs.analchem.6b04436